Cabaletta Bio (CABA) Cash & Equivalents (2018 - 2025)

Cabaletta Bio has reported Cash & Equivalents for 8 years, with the latest figure at $83.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 49.39% year-over-year to $83.0 million; the trailing twelve-month figure through Dec 2025 stood at $83.0 million (down 49.39% YoY), and the FY2025 full-year result was $83.0 million, down 49.39% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $83.0 million, up from $60.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $223.8 million in Q1 2024, with the low at $60.2 million in Q3 2025.
• Average Cash & Equivalents over 5 years is $132.1 million, with a median of $120.7 million recorded in 2021.
• Year-over-year, Cash & Equivalents surged 138.53% in 2024 and tumbled 67.1% in 2025.
• Tracing CABA's Cash & Equivalents over 5 years: stood at $122.2 million in 2021, then sank by 33.23% to $81.6 million in 2022, then surged by 136.79% to $193.2 million in 2023, then retreated by 15.15% to $164.0 million in 2024, then slumped by 49.39% to $83.0 million in 2025.
• The last three Cash & Equivalents figures came in at $83.0 million (Q4 2025), $60.2 million (Q3 2025), and $145.6 million (Q2 2025), per Business Quant data.

Peer Comparison